110 related articles for article (PubMed ID: 8993553)
1. Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo.
de la Iglesia F; McGuire EJ; Haskins JR; Lalwani ND
Ann N Y Acad Sci; 1996 Dec; 804():310-27. PubMed ID: 8993553
[No Abstract] [Full Text] [Related]
2. Peroxisome proliferators: species differences in response of primary hepatocyte cultures.
Elcombe CR; Bell DR; Elias E; Hasmall SC; Plant NJ
Ann N Y Acad Sci; 1996 Dec; 804():628-35. PubMed ID: 8993577
[No Abstract] [Full Text] [Related]
3. Hepatic peroxisome proliferators induce morphologic transformation of Syrian hamster embryo cells, but not peroxisomal beta oxidation.
Sanner T; Mikalsen SO; Rivedal E
Prog Clin Biol Res; 1991; 369():77-89. PubMed ID: 1946545
[No Abstract] [Full Text] [Related]
4. Peroxisome proliferators induce high levels of DNA synthesis in primary cultures of rat hepatocytes.
Bell DR; Plant NJ; Horley NJ; Elcombe CR
Ann N Y Acad Sci; 1996 Dec; 804():745-6. PubMed ID: 8993612
[No Abstract] [Full Text] [Related]
5. Role of eicosanoid metabolism in carcinogenesis by peroxisome proliferators.
Glauert HP; Hong JT; Leung LK; Wilson MW
Ann N Y Acad Sci; 1996 Dec; 804():719-21. PubMed ID: 8993604
[No Abstract] [Full Text] [Related]
6. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat.
Amacher DE; Beck R; Schomaker SJ; Kenny CV
Toxicol Appl Pharmacol; 1997 Jan; 142(1):143-50. PubMed ID: 9007043
[TBL] [Abstract][Full Text] [Related]
7. 32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro.
Gupta RC; Goel SK; Earley K; Singh B; Reddy JK
Carcinogenesis; 1985 Jun; 6(6):933-6. PubMed ID: 4006083
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with peroxisome proliferators protects mice against some but not all hepatotoxins.
Nicholls-Grzemski FA; Burcham PC; Calder IC; Priestly BG
Ann N Y Acad Sci; 1996 Dec; 804():742-4. PubMed ID: 8993611
[No Abstract] [Full Text] [Related]
9. Effect of peroxisome proliferators on intrachromosomal and interchromosomal recombination in yeast.
Schiestl RH; Reddy JK
Carcinogenesis; 1990 Jan; 11(1):173-6. PubMed ID: 2403857
[TBL] [Abstract][Full Text] [Related]
10. Carcinogenicity of lipid-lowering drugs.
Cattley RC
JAMA; 1996 May; 275(19):1479; author reply 1481-2. PubMed ID: 8622215
[No Abstract] [Full Text] [Related]
11. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species.
Gray RH; de la Iglesia FA
Hepatology; 1984; 4(3):520-30. PubMed ID: 6586630
[TBL] [Abstract][Full Text] [Related]
12. Examination of the structural requirements for proliferation of peroxisomes and mitochondria in mouse liver by hypolipidemic agents, with special emphasis on structural analogues of 2-ethylhexanoic acid.
Lundgren B; Meijer J; DePierre JW
Eur J Biochem; 1987 Mar; 163(2):423-31. PubMed ID: 3028804
[TBL] [Abstract][Full Text] [Related]
13. Zonal heterogeneity of peroxisome proliferation in rat liver.
Fahimi HD; Beier K; Lindauer M; Schad A; Zhan J; Pill J; Rebel W; Völkl A; Baumgart E
Ann N Y Acad Sci; 1996 Dec; 804():341-61. PubMed ID: 8993555
[No Abstract] [Full Text] [Related]
14. Peroxisome proliferators and signal transduction.
Bronfman M; Nuñez L; Orellana A; Burzio V; Hidalgo P
Ann N Y Acad Sci; 1996 Dec; 804():403-12. PubMed ID: 8993559
[No Abstract] [Full Text] [Related]
15. Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon.
Reddy JK; Chu R
Ann N Y Acad Sci; 1996 Dec; 804():176-201. PubMed ID: 8993544
[No Abstract] [Full Text] [Related]
16. Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARalpha is functional and mediates peroxisome proliferator-induced hypolipidaemia.
Bell AR; Savory R; Horley NJ; Choudhury AI; Dickins M; Gray TJ; Salter AM; Bell DR
Biochem J; 1998 Jun; 332 ( Pt 3)(Pt 3):689-93. PubMed ID: 9620871
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-kappaB activity.
Li Y; Leung LK; Glauert HP; Spear BT
Carcinogenesis; 1996 Nov; 17(11):2305-9. PubMed ID: 8968042
[TBL] [Abstract][Full Text] [Related]
18. [The mechanism of action of hypolipidemic drugs].
Scheen AJ
Rev Med Liege; 1997 Jun; 52(6):445-6. PubMed ID: 9289779
[No Abstract] [Full Text] [Related]
19. The absence of gamma-glutamyl transpeptidase activity in putative preneoplastic lesions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator Wy-14,643.
Rao MS; Lalwani ND; Scarpelli DG; Reddy JK
Carcinogenesis; 1982; 3(10):1231-3. PubMed ID: 6129072
[TBL] [Abstract][Full Text] [Related]
20. Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats.
Moya-Camarena SY; Van den Heuvel JP; Belury MA
Biochim Biophys Acta; 1999 Jan; 1436(3):331-42. PubMed ID: 9989264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
